Breaking News

Fujifilm Invests $30M in Bio CDMO Business

Increasing monoclonal antibody capacity for process development and GMP production at U.S. and U.K. Sites

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Fujifilm Corporation has unveiled plans to invest roughly $30 million in its CDMO sites in the U.S. and the UK. In addition to investing approximately $20 million in a GMP facility dedicated to the production of monoclonal antibodies at the Fujifilm Diosynth Biotechnologies (FDB) site in College Station, TX, the company is also investing approximately $10 million at its Wilton Centre site in Redcar, UK, to expand the floor area of the development site of production processes for antibodies an...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters